NorthWest Biotherapeutics Inc (NWBO)

[HappyLibrarian]

The science of NWBO has always been solid and it is very good that we got published in a journal and a top-tier journal.

It was mildly surprising to get the article today and not after more months I’ll take it.

Now as to your points:

First, the changing of the endpoints would be of concern to both the authors and peer reviewers if it impacted the scientific integrity of the trial. . But as we can see, neither the authors or reviewers had that concern.

Second, unless you can show how other JAMA articles explicitly spoke to regulatory approval then I do not think that the authors failing to weigh in on that issue (either way) is noteworthy.